Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in Ruxolitinib-refractory or Relapsed Myelofibrosis
CTR20210694Phase 2Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in myelofibrosis (MF), sponsored by Suzhou Zelgen Biopharmaceuticals. Started May 2021; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on CTR20210694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210694.